LAVAL, Que. – Valeant Pharmaceuticals International, Inc. (TSX:VRX) says the U.S. Food and Drug Administration has approved a new Bausch + Lomb disposable contact lens sooner than expected.
Bausch + Lomb was acquired by Valeant for about US$8.7 billion in August.
The prescription lenses use a new material and manufacturing process that the company says will offer improved comfort and vision.
Valeant develops sells a broad range of drugs with an emphasis on dermatology, eye health, and neurology.